Revitaderm Wound Care Gel (benzalkonium chloride 0 — Regulatory Intelligence

Regulatory Event

Blaine Labs Inc, a Santa Fe Springs, California manufacturer, has recalled Revitaderm Wound Care Gel (benzalkonium chloride 0.1%, 1.0 fl. oz. bottles) under a Class I classification confirmed by FDA on July 16, 2026. The firm initiated the recall on April 8, 2026, covering a single lot of 1,171 bottles distributed nationwide in the United States. The reason for recall is microbial contamination of a non-sterile product: quality testing identified Lysinibacillus fusiformis along with other Bacillus species in the affected lot.

It is worth being precise about the product category here, because it changes what “contamination” means clinically. Revitaderm is formulated and marketed as a non-sterile OTC topical gel, not an aseptically manufactured sterile product — it is not held to sterility specifications the way an injectable or ophthalmic product would be, and some level of microbial bioburden control, rather than sterility, is the applicable standard. What makes this a Class I event despite that non-sterile status is the specific use context: a wound care gel is applied to broken or compromised skin, which is precisely the tissue state where organisms that would be harmless on intact skin can establish a local or, less commonly, a more serious infection. Bacillus species, including Lysinibacillus (formerly classified within Bacillus), are generally low-virulence environmental organisms, but a wound care product intended for compromised skin barriers is not a context where “generally low-virulence” is an acceptable substitute for adequate microbial limits control, which is exactly the reasoning behind FDA’s Class I determination here.

What the Record Documents

For a non-sterile topical product, the manufacturing control that failed is microbial limits testing and the underlying bioburden control program — raw material and water-system microbial quality, in-process bioburden monitoring, preservative system effectiveness (benzalkonium chloride itself is a preservative and antiseptic active, so a contamination finding in a product built around an antimicrobial active ingredient raises a specific question about whether the preservative system was challenged and validated against the organisms actually capable of surviving in this formulation), and finished-product release testing against United States Pharmacopeia (USP) microbial limits and objectionable-organism criteria appropriate to a topical product applied to non-intact skin. 21 CFR § 211.113(a) requires appropriate written procedures to prevent objectionable microorganisms in drug products not required to be sterile, and 21 CFR § 211.165(a) requires that each batch be tested or examined and meet its specifications before release. A Bacillus/Lysinibacillus finding of this kind generally points to either a raw material or water-system source that was not adequately controlled or monitored, a preservative system that was not challenged against spore-forming organisms specifically (Bacillus species form spores that are notably resistant to many common preservative systems and to standard cleaning and sanitization protocols), or a release-testing program that did not include sufficient organism-specific screening to catch this contamination before distribution.

What elevates this from a single-lot finding to a facility-level concern is that Blaine Labs has a second, concurrently classified recall in the same window: TERPENICOL Antifungal Solution, recalled for current Good Manufacturing Practice (cGMP) deviations described as discontinuation of required stability testing on products still within expiry, classified the same day as the Revitaderm recall. A microbial-contamination-control failure and a stability-testing-program discontinuation are different manufacturing systems on paper, but both point toward the same underlying condition at a small manufacturer: quality system resourcing or oversight that did not sustain two separate, ongoing control programs simultaneously. Evaluating either finding in isolation would understate what the concurrent classification date is actually showing.

Technical and Quality Context

The closest historical parallel for spore-forming organism contamination in a topical or semi-critical product is the broader industry pattern FDA has documented around Burkholderia cepacia and Bacillus contamination in aqueous-based non-sterile products, which has driven repeated FDA guidance emphasis on water-system microbial control and preservative efficacy testing for exactly this reason: aqueous, non-sterile formulations without robust preservative challenge testing are structurally vulnerable to environmental organism proliferation during manufacture, storage, and in-use handling, regardless of company size. FDA has issued multiple Class I and Class II recalls over the past decade for objectionable organisms — including Burkholderia cepacia complex, Pseudomonas species, and various Bacillus and Ralstonia species — recovered from otherwise unremarkable aqueous-based non-sterile products such as hand sanitizers, oral liquids, and topical gels, frequently traced back to inadequately controlled purified water systems or to raw materials that were not tested for bioburden before use. The pattern across these events is consistent: a non-sterile product is not a product without a microbiological control obligation, and a preservative system validated only against a standard USP (United States Pharmacopeia) challenge panel, without additional consideration of the specific organisms present in a facility’s own water system and raw material supply chain, can leave a genuine gap that surfaces only when a specific problematic organism happens to be introduced.

Any manufacturer of non-sterile topical products, particularly those marketed for use on compromised or broken skin, should independently verify that its preservative effectiveness testing specifically challenges spore-forming organisms rather than only vegetative bacteria and common fungal indicator strains, that its water system and raw material microbial monitoring data are trended rather than reviewed only against a pass/fail limit at each use point, and that stability testing programs are being executed on their required schedule rather than assumed complete based on an initial qualification study. Small manufacturers carrying multiple product lines with limited quality resources should treat a finding in one product line as a prompt to audit whether comparable programs — stability, preservative challenge, microbial limits — are being sustained across every other product line the same facility supports, not only the one named in a given recall.

Decision Relevance

This is where XGene Consulting supports smaller and mid-sized topical and OTC manufacturers directly: microbial limits and preservative effectiveness testing program design and gap assessment, stability program remediation and scheduling audits, and quality system resourcing reviews that identify where a single quality function is being asked to sustain more ongoing control programs than its current staffing or procedures can reliably support. If your facility manufactures multiple non-sterile product lines and you are not confident that every stability and microbial control program across those lines is current, that is worth verifying now, not after a second concurrent finding.